TriMed Research secures €5 million financing

By Jennifer Chiou

New York, June 21 - TriMed Research, Inc. closed Monday €5 million of series A financing, which will be used for the development and clinical trials of MAA, a family of proteins.

The company, a joint venture of the University of Nebraska Medical Center, UNeMed Corp. and Tridelta Development, Ltd., is focused on the development and commercialization of proprietary therapeutic products for intestinal infections.

Investors include inventages venture capital investments, Inc., a fund management company specializing in life sciences, and Seroba Bioventures of Ireland, a venture capital fund.

Erich Sieber of inventages and Alan O'Connell of Seroba will join the board of TriMed.

TriMed's objective is to develop therapeutic products related to the company's patented discovery of the mammary gland protein or MAA, which may reduce bacterial and viral infections in humans and animals.

"This financing will support the next phase of development by allowing us to extend our laboratory findings and enter the clinic," said David Winter, chief executive officer of TriMed, in a news release.

"MAA represents an opportunity for the development and introduction of a new class of anti-infective compounds. Unlike antibiotics, MAA does not have the potential of resistance development and does not fall under the constraints of veterinary use of antibiotic therapy."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.